Aijie Boya Files IPO Prospectus: A Pioneer in Integrated Separation and Purification Solutions with Core Expertise in Separation Materials and Automation
“Having worked with silica for my entire career,” is how Wang Qunjie, Chairman of Aijie Boya Bio Group, describes himself. From his graduate studies through his doctoral and postdoctoral research, Wang Qunjie has been dedicated to silicone materials. After joining Agilent Technologies, he began working with chromatographic separation materials, accumulating profound expertise in silicon-based separation media. Upon leaving Agilent and returning to China, Wang Qunjie founded his own company, achieving the first domestic substitution of silica-based chromatography packing materials in China.
In 2020, Wang Qunjie embarked on a new venture, founding Suzhou Aijie Boya Bioelectronics Technology Co., Ltd. and Zhejiang Boyi Biotechnology Co., Ltd.
In 2022, Suzhou Aijie Boya Bioelectronics Technology Co., Ltd. completed the acquisition of Zhejiang Boyi Biotechnology Co., Ltd., forming the Aijie Boya Bio Group, which integrates industrial chromatographic separation and purification solutions with the R&D and manufacturing of automated pre-analytical systems for clinical mass spectrometry, thereby better serving the biopharmaceutical and clinical mass spectrometry sectors.
Following the completion of the merger and acquisition, Suzhou Aijie Boya Bioelectronics Technology Co., Ltd. has established itself as one of the few companies internationally with chromatographic separation and purification as its core business.Large-Scale High-Purity Spherical Chromatographic Silica Gel Production Base, achieving an industrial breakthrough in the domestic production of silica-based chromatography materials; meanwhile,Pioneered the development of a multi-separation matrix for organic small-molecule extraction: magnetic extraction materials, and in combination with our independently developed fully automated magnetic extraction instrument, it replaces traditional solid-phase extraction methods and is widely used in sample pretreatment for clinical mass spectrometry testing, among other applications.
In addition, Suzhou Aijie Boya Bioelectronics Technology Co., Ltd. offers a wide range of new specialty chromatography separation and adsorption materials, such as organically bonded silica gels with polar, alkali-resistant, and hydrophilic properties, as well as chromatographic media including protein-restricted access and core-shell particles. The company also provides specific adsorbents for trace metals, endotoxins, organic toxins, and phospholipids/proteins in biological samples. These products match international mainstream standards in terms of quality and stability, while offering significant price advantages.
Aijie Boya CollectionSeparation Materials, Equipment Automation, and Purification Process DevelopmentThree leading technologies provide products and total solutions for extraction, separation, and purification.The company is currently focusing on the segments of drug separation and purification, as well as clinical mass spectrometry sample pretreatment, aiming to address the critical “bottleneck” challenges in these two areas.
In the biopharmaceutical market, Aijie Boya focuses on drug separation and purification, including peptides, nucleic acid drugs, synthetic biology, and fermentation. Among these, peptides have been a hot market in the past two years, with oral peptides and GLP targets receiving significant attention. Nucleic acid drugs have gained popularity following the success of mRNA vaccines; over 10 nucleic acid drugs have already been approved overseas, while China’s nucleic acid drug market is also developing rapidly, reaching a scale of hundreds of billions.
The bottleneck in the drug separation and purification market is the import monopoly on extraction and separation materials.Wang Qunjie stated, “Silica-based separation materials commonly used in the field of drug isolation and purification still rely on imports. For instance, while some products are nominally manufactured domestically, key components such as silica raw materials, amino acids used in culture media, and membranes for single-use reaction bags are still imported from abroad.” Hence, there is a saying that “whoever secures the supply of raw materials gains the competitive edge.”
The “bottleneck” of mass spectrometry testing lies in the automation of sample pretreatment, a challenge for which no ideal solution exists globally.
Clinical mass spectrometry offers unique advantages in sensitivity, specificity, and simultaneous multi-analyte detection. Wang Qunjie stated, “Traditional methodologies can detect fatty acids and various hormones in the human body, but they fail to identify certain isomers. They can only measure total bile acid levels, lacking the ability to detect more detailed molecular species. Clinical mass spectrometry can address the limitations of traditional methods, which is highly significant and has ushered in a revolution in diagnostic testing.”
As clinical mass spectrometry is widely applied in areas such as early detection of cardiovascular diseases and risk prediction for metabolic disorders, the future market size is expected to reach at least tens of billions of yuan. However, the widespread clinical adoption of mass spectrometry technology requires automation. Mass spectrometers are inherently scientific instruments not originally designed for clinical testing; thus, their level of automation, reliability, and consistency remains insufficient. In particular, the automation of extraction and separation processes fails to meet clinical requirements, preventing the achievement of the high-level automation seen in biochemical and immunological assays.
“Whether it is materials for drug separation and purification or automation of pre-analytical processing in clinical mass spectrometry, only by achieving complete, genuine domestic production and original innovation can we thoroughly overcome ‘chokepoint’ constraints and enhance the international standing of China’s biopharmaceutical and clinical mass spectrometry enterprises. Suzhou Aijie Boya Bioelectronics Technology Co., Ltd. is accelerating this process.”
Currently, suppliers in the market either provide raw materials, consumables, or equipment, and there is a lack of enterprises capable of offering comprehensive solutions. “A complete extraction and separation solution is an urgent need for downstream customers; its value extends beyond one-stop shopping, providing customers with a more cost-effective option.”
Aijie Boya is not only dedicated to resolving the critical bottlenecks in drug separation and purification as well as automated pre-analytical processing for clinical mass spectrometry, but also takes a step further by pioneering the provision of comprehensive industry solutions, encompassing extraction and separation/purification materials, automated equipment, process development for separation and purification, and related services.
“This is like HP’s printers back in the day: to achieve more ideal returns, one needed to manufacture not only the printers but also the ink cartridges, and even start with the ink itself,” summarized Wang Qunjie.
In the field of separation materials, Aijie Boya has achieved an industrial breakthrough in the large-scale production of silica-based separation materials.Starting from silica sol raw materials, we have produced a series of industrially prepared chromatography resins (including general-purpose, peptide/insulin-specific, and alkali-resistant types), achieving complete domestic production of the mainstream, high-demand silica-based resins in the industry. For instance, in the peptide and insulin separation and purification market, which was previously dominated (>95%) by Japanese and Swedish resin manufacturers for many years, multiple users have now adopted Aijie Boya’s self-produced separation resins and provided feedbackProduct performance fully matches the level of mainstream imported brands., while ensuring excellent separation performance, it reduces packing material costs and offers exceptional cost-effectiveness.
Leveraging the innovations of Aijie Boya, these mainstream chromatography media will no longer be subject to any influence from foreign supply chains or pricing. Currently, the company hasCollaborated with approximately 40 biopharmaceutical companies, with more than ten companies making large-scale purchases with order amounts in the hundreds of thousands.
In terms of instruments, the company has achieved domestic substitution for automated instruments and pioneered multiple original technical methodologies.For example, automated fluid control is achieved through online chromatographic analysis, enabling automated determination of purity, among other functions.
In the clinical mass spectrometry market, Suzhou Aijie Boya Bioelectronics Technology Co., Ltd. is a leading domestic enterprise that has successfully developed magnetic solid-phase extraction technology through independent R&D and commercialized it.
The company’s magnetic solid-phase extraction technology addresses the shortcomings of traditional solid-phase extraction columns, namely their low reliability and inconsistency. Based on magnetic solid-phase extraction technology, the companyEstablished partnerships with over 20 clinical mass spectrometry companies, provides fully automated extraction and purification systems, and jointly develops assay kits. Among these, the company’s mSPE fully automated magnetic bead extraction technology and products have assisted multiple institutions in the development and regulatory submission of assays for catecholamine metabolites, hormones, vitamins, and other analytes.
Wang Qunjie stated, “As a leader in comprehensive solutions for separation and purification, Aijie Boya will focus on key markets in nucleic acid drugs and peptides, rapidly achieving domestic substitution of relevant materials and establishing influence within the industry. The company will collaborate extensively with players in the clinical mass spectrometry market and downstream enterprises to develop complete automated solutions for clinical mass spectrometry. In the longer term, leveraging its core technologies in extraction, separation and purification, and automation, the company will expand into broader application areas and drive more original innovations.”